Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead

Jul 14 2021

• By Anju Ghangurde

indemnity — To Indemnify Or Not, That Is the Question • Source: Alamy

Related Content

With J&J’s COVID Vaccine Pause Now Lifted, The Question Is How Well The System Worked

Apr 24 2021

COVID-19 Vaccine Safety Now: Soft Rollout, Not Pause, After Reports Of Guillain-Barré Syndrome

Jul 13 2021

Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants

Aug 30 2018

Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?

Feb 16 2021

Related Companies

Pfizer Inc.

Moderna, Inc.

Cipla Limited

Johnson & Johnson

BioNTech SE

Emergent BioSolutions, Inc.

Additional Topics

India Asia Pacific Commercial Coronavirus COVID-19 Legal Issues Vaccines BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.